Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene. - Wikidata - wikimedia - TriplyDB

Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene.

Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene.

http://www.wikidata.org/entity/Q37237435

about

Lentiviral vectors in gene therapy: their current status and future potential Towards in vivo amplification: Overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene therapy Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models Aberrant methylation of different DNA repair genes demonstrates distinct prognostic value for esophageal cancer Transduction of human primitive repopulating hematopoietic cells with lentiviral vectors pseudotyped with various envelope proteins.Future alternative therapies for β-thalassemia.Repair of O4-alkylthymine by O6-alkylguanine-DNA alkyltransferases.A zinc-finger transcriptional activator designed to interact with the gamma-globin gene promoters enhances fetal hemoglobin production in primary human adult erythroblasts In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infection Gene therapy for hemoglobinopathies: the state of the field and the future.Therapeutic levels of fetal hemoglobin in erythroid progeny of β-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer.Gene therapy for canine leukocyte adhesion deficiency with lentiviral vectors using the murine stem cell virus and human phosphoglycerate kinase promoters.Cell Membrane-associated heparan sulfate is a receptor for prototype foamy virus in human, monkey, and rodent cells.Chemoselection of allogeneic HSC after murine neonatal transplantation without myeloablation or post-transplant immunosuppression.Efficiency and safety of O⁶-methylguanine DNA methyltransferase (MGMT(P140K))-mediated in vivo selection in a humanized mouse model Gene therapy for β-thalassaemia: the continuing challenge.Gene therapy in thalassemia and hemoglobinopathies.Role of stem cell factor in the reactivation of human fetal hemoglobin.Genetic strategies for the treatment of sickle cell anaemia.Lentiviral vectors and cardiovascular diseases: a genetic tool for manipulating cardiomyocyte differentiation and function.Alternative options for DNA-based experimental therapy of β-thalassemia.Recent advances in gene therapy for thalassemia.Development of gene therapy for thalassemia.Recent trends in the gene therapy of β-thalassemia.The Ongoing Challenge of Hematopoietic Stem Cell-Based Gene Therapy for β-Thalassemia.Lentiviral Transfer of γ-Globin with Fusion Gene NUP98-HOXA10HD Expands Hematopoietic Stem Cells and Ameliorates Murine β-Thalassemia.Chemoprotection in brain tumor patients: another success for stem cell gene therapy.MicroRNA-210 overexpression induces angiogenesis and neurogenesis in the normal adult mouse brain.Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia.Combining gene therapy and fetal hemoglobin induction for treatment of β-thalassemia.

P2860

Q24629462-FE0D5BAA-8792-40AA-AD53-575D8F0E7C1E Q26771159-CB7FC780-E02C-4CD0-A009-36A57925A61C Q26859147-7AC2191B-D1BF-48E7-9482-AFFF779C2F18 Q28240796-36A56F87-1ED5-47A4-8CBF-871D859C9CEA Q30495724-32814CF3-03C4-4172-9D18-7329E82387B5 Q33659678-F5D5E11C-1580-420F-96B4-4C9E261775E2 Q33707101-E9C239BF-9690-4A6A-BB60-E8BB9C764A7D Q33805970-A9D2351E-21B0-4F31-964E-EC3062F1F184 Q34021880-B6C99B7C-BAF5-453E-9E79-76ADC99A4FED Q34204480-FB294E1B-7A04-44CC-B971-1A5D2003257C Q34707143-765CD5C7-83D7-492E-B561-C80110E7ECAE Q35022870-BCBA7999-3463-4570-A26A-42EE383F8F9B Q36014113-64D3E137-62AD-4149-B71E-BE6F6335FE14 Q36401055-2EF6405A-6762-436C-B1AB-4BB5ADAE7200 Q37580086-AA9AF936-6EA9-49E2-85E1-6968274289BC Q37795125-ED5A25C4-8925-4839-A406-A2B99CC6BE56 Q37854468-58C33C6E-2F0C-4CFB-BECB-7B10BF75168F Q37854469-F8B929D7-4101-4B8A-B31A-366E59AD778B Q37894826-9CDD18BE-92A6-495F-ACCA-F47D98F71686 Q37989402-6DC22A46-93AC-4298-82D5-C2B4A266C42B Q37993118-BE7C6044-31BB-4250-95AF-C195F563DE71 Q38038167-62BA03FB-DD92-4137-AC02-9F9007B89F8D Q38057725-75811206-B5A8-481E-8F34-0FB65D546963 Q38367473-8AE78809-A33D-4978-AAE7-2BFDA64D464F Q39749114-E36EA29A-280E-4AEB-ABC6-D2558661EBD1 Q40338871-A3A327C4-D75E-4E19-BE5B-58B78861B420 Q42226731-302F9BAB-3058-4A87-9B6E-C228132045A4 Q42260328-35268411-AD92-4881-91B3-A8DC0148A32D Q45874313-FA4E8D7F-6434-4DE7-B01D-3253DEF58FCD Q45888439-AB68D8A6-76F4-4D23-8B8D-7161A7B9317A

P2860

Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene.

http://www.wikidata.org/entity/Q37237435

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 April 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Amelioration of murine beta-th ...... the MGMT drug-resistance gene.

@en

Amelioration of murine beta-th ...... the MGMT drug-resistance gene.

@nl

type

label

Amelioration of murine beta-th ...... the MGMT drug-resistance gene.

@en

Amelioration of murine beta-th ...... the MGMT drug-resistance gene.

@nl

prefLabel

Amelioration of murine beta-th ...... the MGMT drug-resistance gene.

@en

Amelioration of murine beta-th ...... the MGMT drug-resistance gene.

@nl

P1433

Q37237435-41759991-AEF0-437E-B9B3-FE27A7ED1E32

P1476

Q37237435-8CE15CAF-9D97-422D-A827-BD08229F036B

P2093

Q37237435-40B34B76-48D0-40DB-AAC8-CB88F640F407

Q37237435-7D2AE754-43C7-4DE3-B068-1F5EA894F7CF

Q37237435-9F80BE5A-0664-4F2C-B9F3-5D3053E0ACC8

Q37237435-BE34425C-222D-432D-9666-1E5E376C0238

Q37237435-CCA7F5CB-EEFF-4AF6-A870-EE4F19BD0941

Q37237435-F38B1E20-A181-4AD5-AACC-2214CB9E1991

P2860

Q37237435-04C11C66-1365-4847-B249-F6CF7E7D4D56

Q37237435-100D638D-D96A-484F-A7BF-EBDBDC5F679A

Q37237435-186A2ECF-2AD9-4ADD-A867-1E6766B83EF8

Q37237435-22E823D8-AD25-4583-BF8C-6168A2A896BC

Q37237435-250D6DB4-EF30-461D-B95E-9D9BD638E74A

Q37237435-2755C6D4-C7DE-49BE-B526-F91A15521EE3

Q37237435-2902695A-DCEF-42B4-BDDE-2767DD8AE735

Q37237435-33B0A70F-D6F1-4833-95D6-CAAA9C365F19

Q37237435-3D9CECD0-274B-445F-94BC-27EF9BBC15F7

Q37237435-40873074-06FE-43E7-8C29-0B15E24938CC

P304

Q37237435-7FA6BEA0-B63C-4C38-80F8-281BA6909E63

P31

Q37237435-5780CDDE-9A70-45D3-929B-9BADDB0E368D

P356

Q37237435-B12068BE-A65E-4430-B8FC-83F7A3F1A630

P407

Q37237435-43E29596-29EB-4696-B863-DDDFBA3EF63A

P433

Q37237435-62FB1A4A-31E0-4CD4-BAA7-3DDD906C7BDD

P478

Q37237435-DF458C17-CBE8-457D-8E2C-E9E828B0BE32

P577

Q37237435-8CA661F7-B505-4A03-98A5-F0D9CDADC4C9

P698

Q37237435-41889871-ECEF-4E7A-985D-A1F5F852BE4E

P932

Q37237435-148E6988-FCE5-4F98-A814-7026507E57D9

P356

BLOOD-2008-10-186684

P1433

P1476

Amelioration of murine beta-th ...... the MGMT drug-resistance gene.

@en

P2093

Derek A Persons

http://www.w3.org/2001/XMLSchema#string

Huifen Zhao

http://www.w3.org/2001/XMLSchema#string

Md Nasimuzzaman

http://www.w3.org/2001/XMLSchema#string

Perdeep Mehta

http://www.w3.org/2001/XMLSchema#string

Phillip W Hargrove

http://www.w3.org/2001/XMLSchema#string

Tamara I Pestina

http://www.w3.org/2001/XMLSchema#string

P2860

Erythroid-specific human factor IX delivery from in vivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B mice

Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients

Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector.

Limited lentiviral transgene expression with increasing copy number in an MGMT selection model: lack of copy number selection by drug treatment.

Correction of sickle cell disease in transgenic mouse models by gene therapy.

Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells.

Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs.

Myeloerythroid-restricted progenitors are sufficient to confer radioprotection and provide the majority of day 8 CFU-S.

In vivo selection to improve gene therapy of hematopoietic disorders.

Pois(s)on--it's a question of dose...

P304

5747-5756

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2008-10-186684

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19365082

http://www.w3.org/2001/XMLSchema#string

P932

2700315

http://www.w3.org/2001/XMLSchema#string